Measuring changes to flavoprotein fluorescence (FPF) in the optic nerve of people at various stages of glaucoma could set the stage for a critical new prognostic tool to potentially head off glaucoma before it can cause cell loss and structural damage to the optic nerve, Mount Sinai researchers report.